Swedish CArdioPulmonary bioImage Study 2
Launched by KAROLINSKA INSTITUTET · Nov 6, 2024
Trial Information
Current as of May 18, 2025
Recruiting
Keywords
ClinConnect Summary
The Swedish CArdioPulmonary bioImage Study 2 (SCAPIS-2) is a follow-up to an earlier study called SCAPIS 1, which aimed to learn more about heart and lung diseases by examining over 30,000 men and women aged 50 to 64 from different parts of Sweden. In SCAPIS-2, researchers will re-examine about 15,000 of those original participants between 2024 and 2025. They will use various tests, like heart scans and breathing tests, to gather more information about how these diseases develop and how they might be treated.
To be eligible for SCAPIS-2, you must have participated in the first study (SCAPIS 1). If you have decided to withdraw your consent during or after SCAPIS 1, you won't be able to take part in this follow-up. Participants can expect to undergo similar tests as before, which will help researchers understand the changes in your health over time. This study is important for improving how we identify and treat cardiovascular and lung diseases in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Participated in SCAPIS 1.
- Exclusion Criteria:
- • Individuals who have withdrawn their informed consent during or after SCAPIS 1.
About Karolinska Institutet
Karolinska Institutet is a renowned medical university located in Sweden, recognized for its commitment to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the institution focuses on translating scientific discoveries into effective treatments and therapies, emphasizing patient-centered approaches. With a strong emphasis on collaboration and interdisciplinary research, Karolinska Institutet plays a pivotal role in addressing global health challenges and improving patient outcomes, leveraging its extensive network of experts and state-of-the-art facilities to drive clinical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stockholm, , Sweden
Lund, , Sweden
Uppsala, , Sweden
Linköping, , Sweden
Gothenburg, , Sweden
Umeå, , Sweden
Patients applied
Trial Officials
Carl Johan Östgren, PhD
Principal Investigator
Linkoeping University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported